Published on 30/11/2025

Governance of the Dossier: Reviews and Approvals

The regulatory landscape for biosimilars is both complex and evolving. As the industry prepares and submits dossiers for biosimilar products, adherence to guidelines and understanding comparability studies becomes paramount for approval. This guide seeks to outline the step-by-step governance framework necessary for successful dossier reviews and approvals, particularly focusing on biosimilar analytical comparability, critical quality attribute (CQA) mapping, fingerprint analytics, process drift monitoring, and equivalence testing.

Understanding Biosimilar Analytical Comparability

Biosimilar analytical comparability is the process of demonstrating that a biosimilar product is highly similar to its reference product, notwithstanding natural variability. To navigate through the complex landscape of biosimilar development, it is crucial to grasp the underpinnings of this concept.

Regulatory authorities, such as the FDA, the EMA, the MHRA, and PIC/S have laid out guidelines that define the expectations for biosimilar comparability studies. At the heart of these expectations is the need for robust analytical methodologies to assess similarity between the biosimilar and the reference product.

Establishing CQA Mapping

Critical Quality Attributes (CQA) are the physical, chemical, biological, or microbiological properties that must be controlled to ensure that a product is of the desired quality. Initiating the CQA mapping process involves identifying and characterizing the key attributes of the reference product.

• Identify Key Attributes: Start by reviewing the reference product’s characteristics including potency, purity, stability, and safety profiles.
• Assess Variability: Document and assess the variability in these attributes through historical data and literature review.
• Benchmarking Standards: Utilize established guidelines, such as Q5E comparability guidelines, to establish benchmarks against which the biosimilar can be evaluated.

CQA mapping should be thoroughly documented as it plays a vital role in substantiating the quality and efficacy of the biosimilar. It serves not only to guide the development process but also to support future submissions during the regulatory dossier review.

Fingerprint Analytics: A Tool for Confirmatory Testing

Fingerprint analytics refers to advanced analytical techniques that create a “fingerprint” of a biological product’s attributes. These methods are integral in confirming the biosimilarity between the reference and test products.

Implementing fingerprint analytics involves several steps:

• Technology Selection: Choose suitable analytical techniques such as mass spectrometry, chromatography, or NIR spectroscopy that provide comprehensive and reproducible data.
• Data Generation: Conduct experiments to generate fingerprint data of both the reference and the biosimilar products.
• Comparison Analysis: Use statistical tools and software to analyze the similarity between the fingerprints generated. For example, apply multivariate analysis techniques to evaluate the overlap between the datasets.

Through a rigorous application of fingerprint analytics, developers can provide extensive data supporting the claim of biosimilarity, aiming to alleviate any regulatory concerns during the review process.

Monitoring Process Drift

Process drift refers to the variations that occur in manufacturing processes over time, which can impact the quality attributes of the final product. It is essential to have a strategy in place for monitoring process drift to ensure that the biosimilar consistently meets predefined specifications.

Implementing a PPQ (Process Performance Qualification) and CPV (Continual Process Verification) strategy will allow organizations to maintain control over their manufacturing processes and ensure product quality. Here’s how to integrate these strategies effectively:

• Define Control Metrics: Identify and define metrics that are critical for process monitoring. This can include real-time data on temperature, pressure, pH levels, etc.
• Regular Assessments: Schedule regular assessments of process performance to detect trends and identify deviations before they result in quality issues.
• Documentation: Keep meticulous records of all process parameters and adjustments made, helping to maintain transparency throughout the dossier preparation process.

Effective monitoring and documentation of process drift not only safeguards the quality of the biosimilar but also fulfills regulatory expectations, supporting a smoother approval process.

Equivalence Testing and Bridging Justifications

Equivalence testing is crucial to establishing the similarity between a biosimilar and its reference product. This testing hinges on demonstrating that any differences do not alter the safety and efficacy profile of the biosimilar. Bridging justifications, on the other hand, serve as a narrative that explains any observed differences and reinforces the conclusion of similarity.

To successfully carry out equivalence testing, consider the following:

• Choose Appropriate Testing Methods: Select methods such as clinical trials, pharmacokinetic studies, and immunogenicity assessments that will substantiate the claims of equivalence.
• Statistical Rigor: Use robust statistical analyses to evaluate the results of equivalence testing, ensuring that your conclusions are data-driven.
• Document Justifications: When differences are observed, it is critical to document comprehensive justifications based on scientific literature, historical data, and expert opinions.

Bridging justifications are significant for addressing any concerns raised during the dossier review and to support the claims for approval by authorities such as the EMA or the FDA.

Putting Together the Dossier: Best Practices

The compilation of the regulatory dossier is a pivotal step towards securing approval for a biosimilar. A well-structured dossier not only simplifies the review process but also stands as a testament to the quality of the product. Below are best practices for Dossier preparation:

• Regulatory Framework Compliance: Familiarize yourself with and adhere to the guidelines set forth by regulatory authorities, including Q6B specifications for biopharmaceutical products and language stipulated by regulatory bodies.
• Consistency in Data Presentation: Ensure that all data and documentation are presented in a consistent and logical format throughout the dossier, enhancing clarity for the reviewers.
• Incorporate Feedback: Engage with regulatory authorities early in the process and incorporate their feedback into the dossier to minimize the likelihood of substantial revisions later.

Overall, a well-prepared dossier is instrumental in facilitating a more efficient review process, aligning with the expectations of regulatory agencies.

Conclusion: Ensuring Dossier Success

The governance of the dossier is a critical process for the successful approval of biosimilar products. By adhering to best practices in biosimilar analytical comparability, effective CQA mapping, the application of fingerprint analytics, diligent monitoring of process drift, and robust equivalence testing with detailed bridging justifications, pharmaceutical organizations can enhance their dossier’s likelihood of a successful review and approval.

In conclusion, it is imperative to maintain rigorous compliance with the regulatory framework and continually seek updates in guidelines from organizations like the WHO to ensure alignment and preparedness for the challenges and opportunities that the biosimilar market presents.